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Abstract  
 
 The growth of a tumor depends on de novo angiogenesis, which involves multiple 
signaling cascades and is also a target for many anti-angiogenic therapies. Epidermal 
growth factor like (EGFL7), is a protein that is expressed by endothelial cells during 
angiogenesis and is necessary for the proper assembly of a sprout. However, EGFL7 is 
also upregulated in many tumors such as glioma and non-small cell lung cancer,  and 
associated with poor patient prognosis. We have previously shown that EGFL7 
expression by tumor cells inhibits tumor angiogenesis, which is contrary to its 
requirement for angiogenesis when expressed by endothelial cells. As a result, the 
objective of this research is to understand the basis of this differential regulation. We 
hypothesize that the differential effects of EGFL7 on angiogenesis are due to the 
presence of alternative transcripts in HT1080 tumor cells. One common method of 
regulation is transcriptional regulation which can involved the generation of multiple 
alternative transcripts due to the presence of different transcriptional start sites. Here, I 
demonstrate that endothelial cells express two families of transcripts, TSS1 and TSS2 
families, which are transcribed from two different transcriptional start sites. In HT1080 
tumor cells, however, only TSS2 families of transcripts are produced. Importantly, novel 
a novel non-coding transcript in both TSS1 and TSS2 family were identified. Non-coding 
transcripts are known to have important roles in global transcriptional regulation, such as 
chromatin remodification. Knocking down TSS2 transcripts in tumor cells resulted in 
enhanced angiogenesis. Result from this thesis identify novel differential EGFL7 
transcripts expressed in HT1080 tumor cells, which inhibits angiogenesis.  
 Key	  words:	  EGFL7,	  Angiogenesis,	  Differential	  regulation,	  transcripts	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Chapter 1: Introduction  
 
1.1 Overview  
The vasculature acts as a conduit for the delivery of nutrients, oxygen or other factors 
and is therefore necessary for homeostasis but also plays a role in tumor development. 
The formation of new blood vessels from pre-existing vasculature is defined as de novo 
angiogenesis [1]. The formation of blood vessels begins in development through 
vasculogenesis, a process in which a primitive vascular network forms due to 
differentiation of mesodermal precursor cells into endothelial progenitor cells (EPC) or 
angioblasts [2]. The vasculature eventually matures through sprouting angiogenesis or 
intussusception. In the adult, angiogenesis occurs primarily through sprouting due to the 
presence of an angiogenic stimulus such as growth factors, however, EPC’s have been 
documented to incorporate into a newly formed vessel. In the adult, angiogenesis occurs 
during physiological processes such as wound healing and in pregnancy, but in 
pathological states such as tumor progression, sustained angiogenesis is maintained by an 
abundance of pro-angiogenic signal competing with inhibitory signals [3,4]. The 
angiogenic microenvironment in tumors is regulated by a variety of secreted extracellular 
factors and autocrine or paracrine signaling amongst endothelial cells making up the 
vasculature and tumor cells.  
 
Amongst the many secreted factors in the extracellular microenvironment in tumors, 
epidermal growth factor like-7 (EGFL7) has recently been identified as a novel player 
involved in the proper alignment and spatial organization of endothelial cells during 
sprouting angiogenesis. This protein, when exclusively expressed in endothelial cells, has 
been shown to be required for proper vasculogenesis and angiogenesis [5-8]. 
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Interestingly, EGFL7 has also been upregulated in many malignant tumors such as colon 
cancer, hepatocellular carcinoma, non-small cell lung cancer and glioblastoma. We have 
previously shown that EGFL7 expression in HT1080 tumor cells acts to inhibit 
angiogenesis. This was observed both in vitro and in vivo in the chick chorioallantoic 
membrane (CAM), which is a vascular membrane that can be used to visualize 
angiogenesis through intravital imaging or microscopy. This consequently reduced 
metastasis of tumor cells. After observing sprout morphology, the endothelium was no 
longer a monolayer but endothelial cells were layered on top of one another.  
 
Given that in HT1080 tumor cells EGFL7 acts to inhibit angiogenesis but when 
expressed by endothelial cells it is necessary for angiogenesis, I investigate how EGFL7 
is being differentially regulated in HT1080 tumor cells and the subsequent impact this 
has on tumor angiogenesis. We hypothesize that HT1080 tumor cells express alternative 
transcripts in comparison to endothelial cells and this method of differential regulation 
mediates EGFL7’s inhibitory effect in tumor cells.  
 
1.1.1 Overview of angiogenesis 
 
De novo angiogenesis is defined as the formation of new blood vessels from pre-existing 
vessels [9]. Angiogenesis is a necessary process for the supply of oxygen, nutrients, 
transport of immune cells and other factors necessary for maintaining tissue physiology-
physiological angiogenesis [10]. However, during pathological conditions the vasculature 
can be aberrantly activated to generate new blood vessels in disease states such as cancer 
and chronic inflammation.  Angiogenesis dependent diseases results when new blood 
2	  
	   	   	   	   	   	   	   	   	   	  
vessels grow excessively or insufficiently as in cases of coronary artery disease, stroke 
and wound healing [11]. The key to dictating the angiogenic environment is a balance 
between angiogenic stimulators such as fibroblast growth factors (FGF) and angiogenic 
inhibitors, such as endostatin and maspin[12-13]. In disease states, this balance dictates 
the progression of the formation of new blood vessels.   
 
  Angiogenesis is mediated by two distinct mechanisms known as intussusception 
and sprouting [Fig1-1][14]. During sprouting angiogenesis, quiescent endothelial cells 
(EC) become activated by angiogenic signals binding to EC receptors, often in the form 
of a gradient [15-18]. This causes endothelial cells to form loose junctions, proliferate 
and migrate towards the gradient in a characteristic stalk-tip cell formation. This is 
further accompanied by the secretion of extra-cellular matrix (ECM) enzymes, which 
degrade the surrounding ECM. Eventually, these endothelial cells coalesce to form tubes 
known as tubulogenesis, and become stabilized by other cell types such as pericytes. 
However, during intussusceptive angiogenesis, transluminal tissue pillars form within 
capillaries as a result of endothelial cells fusing together [19-21]. This process follows 
precise stages where protrusion of opposite side of capillary walls precedes inter-
endothelial cell contact. Collagen fibrils are then deposited leading to tissue expansion 
and formation of new tissues.  The angiogenic process is a highly coordinated process 
requiring diverse regulatory pathways, multiple cell types and presence of many ECM 
proteins. As a result, it is an attractive therapeutic target for disease processes such as 
cancer.  
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Fig.1-1 Angiogenesis: Sprouting and Intussusceptive Growth. 
A)Sprouting angiogenesis is initiated by a stimulus in the ECM, such as growth factors, hypoxia 
or angiogenic factors which initially causes the loosening of endothelial cells subsequently 
acquiring a tip-stalk arrangement. B)The filopodia rich tip cells sense the stimulus gradient while 
stalk cells help elongate the newly formed sprout. C) This eventually forms into a mature network 
of vessels that coalesce together. D) In intussusceptive growth, endothelial cells (EC) on opposite 
side of the capillaries protrude into the lumen contacting each other. Once contact is established, 
the contact forms interendothelial junctions and the endothelial bi layer is perforates centrally. 
Endothelial cells are then invaded by fibroblasts and pericytes where collagen is deposited 
between the two vessels. Image from [14,15] 
	  	  
A)	  
B)	  
C)	  
D)	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1.1.2 Overview of Vasculogenesis 
The vascular plexus formation is necessary in the developing embryo to enable delivery 
of oxygen and nutrients and removal of metabolic waste in the developing embryo. Many 
factors influence the differentiation and commitment of many cells types involved in the 
vascular plexus formation during gastrulation phase. The gastrulation phase occurs 
during the early phase of development in which the blastula is re-organized into the 3 
germ layers-mesoderm, ectoderm and endoderm.  The mesoderm layer of the embryo is 
comprised of mesenchymal cells that gives rise to the circulatory system [22]. The 
formation and development of de novo blood vessels from EC precursors is termed 
vasculogenesis. Vasculogenesis occurs in the extra-embryonic yolk sac, a membranous 
sac that provides nourishment to the embryo. In this particular process mesenchymal cells 
differentiate into endothelial progenitor cells (EPC) forming characteristic aggregates 
known as blood islands [Fig 1-2] [23,24]. Ultimately, these blood islands fuse together 
which form the primitive capillary plexus. This primary capillary plexus under the 
control of a variety of molecular signals can undergo angiogenesis (sprouting and non-
sprouting). Subsequently, vessels undergo pruning remodeling, where the vessels have a 
characteristic shape of a tree with large and small vessel branching. Following pruning 
remodeling, organ-dependent maturation remodeling occurs, where the vessels either 
mature or regress in the organ they supply. Furthermore, the particular organ will 
influence the shape of vessels based on extra-luminal factors such as platelet derived 
growth factor (PDGF) [25].  
 
        Vasculogenesis however is not limited to the embryo. Asahara et al (1997), 
determined CD34+ CD45- EPC’s (angioblast) isolated from human blood can 
5	  
	   	   	   	   	   	   	   	   	   	  
differentiate into endothelial cells in vitro [26]. This cell arises from a precursor 
multipotent bi-potential hemangioblast originating from the bone marrow and capable of 
hematopoiesis or angiogenesis [27]. Growth factors, cytokines and chemokines secreted 
by the hypoxic environment or tissue injury induces the proliferation, differentiation and 
mobilization of EPC to sites of new-vessel formation [28]. How EPC home to an area 
undergoing angiogenesis is not well known. Once at the site of ischemia, EPC co-
ordinate with pre-existing EC’s to stimulate angiogenic sprouts or EPC’s can differentiate 
into mature EC's that incorporate into neo-vessels. Although this cell type has been 
previously identified in an angiogenic sprout, the molecular mechanisms for 
differentiation remain elusive [29,30] 
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Fig. 1-2 The process of vasculogenesis 
The process of vasculogenesis begins with induction of mesodermal precursors, which 
differentiate into a bipotential hemangioblast, capable of giving rise to the hematopoietic and 
vascular system. The angioblast lineage forms blood islands giving rise to primary vascular 
plexus. Subsequent angiogenesis occurs through sprouting, and intussusception. Vascular 
remodel and maturation occurs in an organ-specific manner through the recruitment of 
pericytes and vascular smooth muscle cells.  Green, are molecules involved in the 
development of processes (red). A; arteriole, V, venule. Image from [2] 
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1.1.3 The Molecular Mechanism of Sprouting Angiogenesis 
        Sprouting angiogenesis is the formation of a new sprout from a parental vessel, 
eventually forming a neo-vessel. The steps of angiogenic sprout formation can further be 
subdivided into 3 separate phases: quiescence, activation and resolution [Fig 1-3][31-33]. 
During quiescence endothelial cells are protected against insults from their surrounding 
environment through autocrine signaling of angiopoietin (ANG-1), vascular endothelial 
growth factor (VEGF) and fibroblast growth factors. ECs can sense oxygen levels 
through hypoxia-inducible factor prolyl-4 hydroxylase (PHD2) and hypoxia inducible 
factor-2 alpha (HIF2α). HIF’s are transcription factors that are activated when tissue 
oxygen levels decrease to below 6%/40mmHg and bind to hypoxia responsive cis-
elements associated with vessel growth [34]. Moreover, ECs form a monolayer of 
phalanx cells with tight claudins and vascular endothelial-cadherin junctions. These 
proteins are necessary for maintaining the restrictive permeability of endothelial cells 
through strong cell-cell adhesion. However, other types of junctions exist such as 
desmoplakin, which is also involved in adhesion. The pericytes which ensheath 
endothelial cells produce a common basement membrane but also generate cell survival 
signals such as ANG-1 and VEGF-2.  
 
However in activation phase, the sensing of angiogenic signals such as VEGF, 
FGF’s, ANG-2, causes endothelial cells to acquire an activated phenotype in which 
pericytes detach from vessel walls and begin migrating towards the gradient of sensory 
signals by first degrading the basement membrane by release of proteolytic enzymes such 
8	  
	   	   	   	   	   	   	   	   	   	  
as matrix metalloproteinases  [35]. Furthermore, endothelial cells loosen their junctions 
and VEGF increases the permeability of vessels. This causes the extravasation of plasma 
proteins which create a permissive scaffold for the proper migration of endothelial cells 
[36]. The migration of endothelial cells is mediated by integrin signaling. Proteloytic 
cleavage activates inactive angiogenic factors in the ECM, such as VEGF or FGF [37]. 
To prevent a mass of endothelial cells moving towards the sensing signal, the nascent 
vessel acquires a stalk-tip phenotype where a tip cell gets selected and becomes a 
filopodia rich sensor in the presence of factors such as neuropilins (NRP’s) and NOTCH 
ligand, delta like-5 (DLL5) [38]. The tip cells respond to environmental cues such as 
ephrins and semaphorins. The remaining stalk endothelial cells however elongate and 
proliferate pushing the sprout towards a signal stimulus [39]. They also secrete epidermal 
growth factor like-7 (EGFL7) to maintain the spatial organization of cells.  
 
Eventually, endothelial cells will coalesce together and pericytes aid with the 
fusion with another vessel branch [40-42]. Endothelial cells acquire a stable and mature 
phenotype as they acquire their phalanx state phenotype and signals such as TGF-B, 
ephrin-B2 causes cells to become covered with pericytes [43]. Once pericytes re-establish 
contact with endothelial cells, induction of tissue inhibitor of metalloproteinases (TIMP) 
halts the proteolytic nature of tip cells. TIMPs also cause the deposition of the basement 
membrane and tight junctions and adherens junctions are further re-established [44]. 
Other cell types such as smooth muscle cells stabilize the resulting blood vessel. 
Subsequent blood flow to the completed mature vessel raises local oxygen levels 
resulting in a decrease of  vascular endothelial growth factor-A (VEGFA) and the 
induction of endothelial cell quiescence [45].  
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Fig.1-3 Molecular Mechanisms of Sprouting Angiogenesis.  
A) The quiescent state of endothelial cells (red) is maintained by the pro-survival autocrine 
signaling of a variety of factors such as VEGF, NOTCH and ANG-1. B-D (Activation phase). 
B) Extracellular signaling of growth factors such as VEGF  or hypoxia causes the activation 
of endothelial cells and liberation of pericytes (green). C) The release of proteolytic enzymes 
such as MMPs (red spheres) causes the degradation of the basement membrane (purple line) 
and the extracellular matrix. Additionally, VEGF increases permeability of endothelial cells 
allowing serum proteins (green squares) to be laid down on the provisional matrix. D) Stalk 
cells undergo proliferation (circular cells) while tip cells  (cells with protrusions) extend 
filopodia to sense their surrounding and respond to growth factor gradient. E) During the 
resolution phase, endothelial cells coalesce together and factors such as TGF-B, Ephrin-B2 
causes the recruitment of pericytes and TIMP inhibits release of proteolytic enzymes from tip 
cells. It is not known whether pericytes are involved in establishing the contact between tip 
cells. Modified from [31] 
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1.1.4	  Overview	  of	  Tumor	  Growth	  &	  Tumor	  Angiogenesis	  
The growth of a tumor is considered as deregulated and uncontrollable growth of 
cells in any particular tissue. The development of tumor is dependent on many 
environmental and hereditary factors. However, the transformation of a normal cell to a 
cancerous type often is due to accumulation of genetic mutations [46]. These mutations 
can be chromosomal aberrations such as additions, deletions or inversions. Other 
mutations can be simple point mutation in the genetic code. The hallmarks of cancer that 
collectively dictate malignant growth are as a result of manifestations that are shared by 
all tumors: self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, 
limitless replicative potential, sustained angiogenesis, evasion of apoptosis or 
programmed cell death, and tissue invasion and metastasis [Fig 1-4] [47-49]. The updated 
version of these manifestation also included different forms of biological stressors such 
as mitotic stress, oxidative and DNA damage stress. Cancer can arise when oncogenes 
that are involved cell growth become activated or alternatively when tumor suppressor 
gene become inactivated [50]. These genes can be involved in cell death due to sensing 
DNA damage (i.e. p53). Many humans have cancer cells but are kept in check by 
immune mechanisms and often can’t induce angiogenesis. These tumors are said to 
acquire a dormant phenotype or regress [51]. However, an angiogenic switch to a pro-
angiogenic milieu can result in the recruitment of blood vessels and subsequent 
development of tumors.  	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Fig. 1-4. The Hallmarks of Cancer 
There biological capabilities, which are acquired during tumor development. The 
purpose of these descriptions are to rationalize the complex nature of neoplastic 
disease. They include proliferation signals, evasion of growth suppressors, evasion 
of apoptosis, sustained angiogenesis, tissue invasion and metastasis, limitless 
proliferative ability and different forms of biological stress. From [47] 
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Passive diffusion in interstitial tissue provides avascular tumors oxygen and 
nutrient and limits the tumor size to 1-2mm3 [52]. However, tumor beyond this size 
trigger angiogenesis [Fig 1-5]. Most often, the angiogenic switch is turned on as a result 
of local hypoxia. Activation of angiogenic switch is mediated by cytokines, oncogene 
activation and inactivation of tumor suppressor genes. Transcription of hypoxia related 
genes induced by HIFs and their over-expression has been previously correlated with 
poor prognosis [53-55]. The cascade of tumor angiogenesis resembles normal 
angiogenesis, however with some key differences. Tumor cells themselves tend to 
overexpress a variety of angiogenic proteins such as FGF, VEGF and ephrins [56]. The 
overexpression of these factors often deregulates the proper formation of blood vessels 
surrounding tumors causing tumor vasculature to be tortuous/leaky due to affecting the 
stability and proper arrangement of endothelial cells. This, however, further leads to poor 
delivery of oxygen and nutrients. Activated	   platelets	   further	   release	   angiogenic	   and	  permeability	  factors	  in	  the	  local	  environment	  [57,58].	  	  	  	  In	   response	   to	  hypoxia,	   tumors	   tend	   to	   release	  a	  variety of ECM proteins to 
which foster tumor expansion and accommodates tumor growth. Tumor cells also release 
a range of soluble factors such as myeloid differentiation antigen-1 (Gr1), 
phosphatidulinositol-3 kinase (PI3K) that are involved with the mobilization of myeloid 
cells from bone marrow and subsequent differentiation into tumor associated 
macrophages [59-61]. In the context of PI3K’s, they phosphroylate various 
phosphoinositides which recruit various proteins to the cellular membrane involved in 
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cellular proliferation, differentiation and cell survival. The interaction between 
endothelial cells with other cell types and ECM proteins leads to their migration, survival 
and proliferation. Importantly, interactions between immune cells and endothelial cells or 
cross-talk pathways between different cell types can suppress or augment endothelial 
activation [62].	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Fig.1-5 The Development of Tumor Angiogenesis.  
Tumor angiogenesis occurs through the interaction of a variety of cell types. Tumor 
cells abundantly express VEGF which binds to VEGFRs. Binding to VEGFR1,2,3 
causes lymphoangiogenesis, proliferation of stalk endothelial cells and recruitment of 
EPCs, respectively. This ultimately establishes an angiogenic environment of tumor 
growth and metastasis. From [60] 
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         Eventually after the tumor grows the angiogenic enviornmnet allows tumor cells to 
proliferate, migrate and intravasate into the vasculature [63,64]. After intravasation, 
tumor cells can be suspended in the vasculature or metastasize to another distant tissue 
[Fig 1-6]. During this process, tumor cells extravasate into tissues to form a secondary 
tumor. However, it is important to note that out of all the cancer cells that metastasize 
only a small number of cells survive as metastasis is an inefficient process [65]. This 
concept suggests that there are only a few cancer cells that have the potential to make it 
to a secondary site. Most other cells die during the process or at the secondary site. Each 
phase of tumor development originating from primary tumor	   growth	   to	   secondary	  growth	  involves	  changes in the genetic program of tumor cells, potentially making them 
resistant to targeted therapies [66].  Metastasis is 90% of human cancer related deaths and 
consequently targeting the tumor vasculature is a favorable approach.	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Fig 1-6. The Metastatic Process. 
The metastatic process involves the growth of a primary tumor, invasion of the tumor 
through the stroma and ultimatley intravasation into a vessel. Upon intravasation, 
tumor cells  can travel to distant sites extravasate to another tissue. The process of a 
secondary site tumor formation in-efficient due to cell death but cells can also remain 
dormant and re-activated. From [65] 	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1.2 EGFL7  
1.2.1 EGFL7 expression by endothelial cells  
Epidermal growth factor like-7 (EGFL7) also known as vascular endothelial statin was 
identified by 3 laboratories as a endothelial specific gene expressed during 
embryogenesis [67-70]. EGFL7 is a 30kDa protein that is abundantly expressed by 
proliferating endothelial cells during embryogenesis, physiological and pathological 
angiogenesis. EGFL7 transcripts are first observed in endothelial cells at the 8-cell 
morula stage, which are undifferentiated ball of cells contained in the zona pellucida. 
EGFL7 transcripts can also be observed both in the extra-embryonic and embryonic 
mesodermal progenitors which are precursors for endothelial cells [69]. After birth 
however, EGFL7 expression levels decrease but expressed in a subset of vessels within 
the heart, spleen, liver, lungs and heart. EGFl7 expression is also expressed in the 
developing post-natal retinal vascular plexus, in which sprouting angiogenesis dominates. 
EGFL7 in this case is localized to the basal side of stalk cells showing patchy expression 
in tip cells.  During physiological angiogenesis however, EGFL7 becomes elevated. 
EGFL7 expression is elevated in the endothelium of the pregnant uterus and increased 
levels are observed after vascular injury including hypoxic insults[70], arterial injury [69] 
in coronary artery disease, solid tumors[4] or other cases of pathological angiogenesis 
[71-72]. EGFL7 expression has also been observed in neurons of the adult mice and 
primordial germs cells suggesting alternate roles in different tissues [73].  In summary, 
the spatial and temporal profile expression pattern of EGFL7 indicates a function of this 
protein in vascular formation and remodeling. 
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   With the exception of stem cell population and neurons, EGFl7 expression remains 
restricted to the endothelium. All other angiogenic molecules are secreted by a diversity 
of cell types in the angiogenic environment. VEGF for instance is expressed by a variety 
of cell types such as macrophages [74], aortic smooth muscle cells [75] and epithelial 
cells [76]. As a matter of fact, the endothelium is a minor source of VEGF. EGFL7 
however, is uniquely and abundantly secreted by endothelial cells and for this reason is 
an excellent marker for endothelial cells.   
	  
1.2.2 EGFL7 Gene Structure and Regulation	  
The mouse and human Egfl7 genes are located on chromosome 2 and 9 
respectively [77]. Both human and mouse genes span a size of approximately 10kb.  In 
humans, the Egfl7 gene comprises 10 exons, in which exons 3 to 10 are the open reading 
frame of the EGFL7 protein [Fig1-7]. The only ATG site of the Egfl7 gene is located at 
exon 3. Between exons 7-8 or alternatively intron 7, the gene houses microRNA-126. 
This microRNA is implicated in vascular integrity and angiogenesis [80]. miR-126 has 
also been implicated in cardiovascular diseases and development of tumors [78-79]. The 
5.4 kb promoter fragment positioned directly upstream exon 3 contains two evolutionary 
conserved transcriptional start sites, TSS1 and TSS2.  The upstream promoter also houses 
2 non-coding exon and a partial non-coding region on exon 3. The TSS1 is situated in 
non-coding exon 1 and TSS2 is located just upstream of exon 3, between non-coding 
exon 2 and exon 3. It has been previously documented that EGFL7 expresses multiple 
transcripts. The promoter region contains Ets (E-twenty six) transcription factor binding 
sites for Erg (Ets related gene), Fli-1 (Friend leukemia integration 1 transcription factor), 
which have been shown to be necessary for expression of EGFL7 reporter gene in the 
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endothelium in adult tissues and during embryogenesis [80]. However, Ets binding sites 
do not contain FOX/ETS motifs, which is a composite cis-acting element that can bind to 
FOX:ETS transcription factors synergistically [81]. These factors transcribe VEGFR2, 
Notch4, tie2 genes necessary for angiogenesis. Through site-directed mutagenesis studies, 
it has been observed the EGFL7 promoter region also contains a GATA consensus 
sequence suggesting that GATA transcription factors, like GATA-2, are also involved in 
modulating EGFL7 expression [82].  Both ETS and GATA sites are important for 
endothelial development by promoting differentiation of these cells. Furthermore, Le 
Bras et al (2010), concluded that targeting Fli-1, Erg and GATA-2 transcription factors 
using siRNA reduces EGFL7 protein levels [82].  
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Fig 1-7. The EGFL7 Locus 
The EGFL7 gene locus comprises 10 exons. The 5’end contains 2 untranslated exons (white) 
and two transcriptional start sites (TSS1, TSS2). The ORF of the gene is from exon 3 to exon 
10 (red). Intron 7 contains the sequence for miR-126 processing.  
TSS1	   TSS2	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1.2.3 EGFL7 Protein 
 
The EGFL7 protein is a highly conserved protein among species. Recombinant and 
native EGFL7 protein has a mass of approximately 41Kda, after post-translation 
modifications such as several potential N- and O-linked glycosylation at several sites. 
These are sites located on the protein where sugar moieties can bind to and potentially 
alter their interaction in the extracellular matrix. The EGFL7 protein sequence consists of 
amino signal peptide, an EMI domain and 2 EGF-like domains [Fig1-8] [6]. These motifs 
are commonly found in many proteins secreted in the ECM, as they are often used with 
interaction to ECM proteins [83,84]. This is suggestive that EGFL7 has an extracellular 
role. One of the EGF-like domains contains a Delta-Serrate, LAG-2 (DSL) domain that 
binds to Notch, which is also a key regulator of angiogenesis [85,86]. However, the 
second EGF-like domain binds to calcium. The EMI domain of EGFL7 is found 
commonly in many ECM proteins and associated with regulating cell adhesion and 
multimerization[87]. Supporting the idea that EGFL7 is a ECM protein, 
immunohistochemitry of EGFL7 reveals it is a localized to organelles of the secretory 
pathway in over-expressing cell cultures [67, Soncin]. EGFL7 has also been found to be 
secreted in the supernatant of cultured cells [6, 67, 88].	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Fig.1-8 The EGFL7 Protein 
The EGFL7 protein comprises 4 domains.  A signal peptide in the N-terminus 
which dictates extracellular release of the protein, a EMI domain and 2 EGF-like 
domains, of which the distal domain belongs to Ca2+ binding EGF-like domains. 
The presence of EGF domains further elucidate a extracellular role for EGFL7, as 
they are commonly found in ECM proteins.  
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1.2.4 Role of EGFL7 expression by endothelial cells during sprouting angiogenesis  
In contrast to vasculogenesis, angiogenesis involves the formation of new blood 
vessels from pre-existing vasculature. The angiogenic process is a highly co-coordinated 
process involving multiple steps: vasodilation, endothelial cell activation and 
permeability, proliferation and migration, lumenization and	   endothelial	   cell	   survival	  and	   vascular	  maintenance	   [89].	   Based	   on	   EGFL7’s	   role	   during	   tubulogenesis,	   it	   is	  
safe to hypothesize a similar role during sprouting angiogenesis. To study the function of 
EGFL7 during sprouting angiogenesis, Schmidt et al (2007). generated two mouse 
models with EGFL7 deletions [88]. The first model was a retroviral gene trap inserted in 
intron 2, upstream of the translation initiation codon in exon 3. The second mouse line 
was generated by homologous recombination resulting in the removal of exon 5 to exon 
7. Approximately 50% of EGFL7 -/- mice died in utero and the rest of the mice developed 
compromised lumens with severe vascular defects. A delay in the development of the 
vasculature was observed in cranial, coronary and retinal areas. These phenotypes 
however were later resolved in the later developmental stages. This could be explained by 
the fact that EGFL7, an orthologue of EGFL7 was upregulated in these tissues. EGFL8 
and EGFL7 both share similar domain structure and similar expression pattern with 35% 
protein homology [90]. The fact that zebrafish embryos never did recover, but mice did 
recover from EGFL7 deletions could be explained by the fact that zebrafish lack the 
EGFL8 paralogue [4]. To examine the cellular basis of vascular defect observed, they 
further examined the angiogenic sprout morphology.	  	  	  
During angiogensis, tip cells are selected and sense a gradient of angiogenic signal 
leading the sprouting vessel. The stalk cells however, proliferate and further elongate the 
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sprouting tip. In wild type animals, tip and stalk cells organize themselves in a single cell 
layer [91]. However, EGFL7-/- mice arrange themselves in multiple cell layers, forming 
aggregates [88]. Immunohistochemical staining of collagen IV indicated that they were 
localized within the sprouting vessels in comparison to between vessels [88, 4]. This 
concludes that endothelial cells lacking EGFL7 cannot detect sprouting boundaries, 
suggestive of EGFL7 role as a	   boundary organizing ECM protein dictating	   proper 
organization of endothelial cells [Fig 1-9]. In support of this observation, it has been 
previously been observed that EGFL7 supports the adhesion of endothelial cells to the 
ECM  [69]. More specifically, it creates an environment where cells can attach and 
detach until positioned properly. When EGFL7 is missing the cells clump together 
endothelial cells cannot migrate and thus sprouting angiogenesis is delayed.	  	  	  
	  	   The Notch pathway is a highly conserved signaling pathway conserved in most 
multicellular organisms [92-95]. Mammals possess four different Notch receptors 
(NOTCH1, NOTCH2, NOTCH3 and NOTCH4). The receptor is a single pass 
transmembrane protein with a large extracellular portion, a single transmembrane pass, 
and a small intracellular region known as notch intracellular domain (NICD). The 
binding of notch to its five canonical ligands, Delta 1, 3, 4, or jagged1 and 2, which are 
also single pass transmembrane proteins, promotes proliferative signaling and 
angiogenesis. The specific mechanism is the translocation of the NCID into the nucleus 
promoting transcription of many target genes. It has been shown that EGFL7 acts to 
inhibit notch signaling by binding to Notch on tip cells and competing with jagged type 
ligands [96]. This can have important implications for the vascular system since Notch 
has an important role in tip-stalk cell fate determination [97-98]. High levels of Dll4 on 
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tip cells activate notch receptors present on adjacent stalk cells. This suppresses the 
tip cell phenotype by mechanisms that remain unclear. The presence of EGFL7 therefore 
acts to promote the tip cell phenotype.  	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Fig1-9. EGFL7 expression by endothelial cells during sprouting angiogenesis. 
EGFL7 is expressed by endothelial tip and stalk cells during the development of a vessel. 
Through fluorescence studies, it has been shown that EGFL7 is localized to the 
surroundings of a sprout. EGFL7 seems to dictate the spatial arrangement and boundary of 
a sprout.   
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1.2.5 EGFL7 during Vasculogenesis 	  
Evidence of the role of EGFL7 in the vasculature was presented by Parker et al 
(2004), in which they were interested to understand the role of EGFL7 during vascular 
tube formation during vasculogenesis [4]. During the process of primitive plexus 
formation cells do not simply assemble into tubes but form aggregates attached to each 
other eventually forming cord like structures, which then form a vascular lumen, also 
known as tubulogenesis. Over-time angioblasts gradually separate from the	  cords	  during	  the	   cord-­‐tube transition as a result of loosening of junctions between endothelial cells 
[99-100]. However, in zebrafish that lack EGFL7 the process of angioblast separation is 
impaired and tubes cannot be formed. Thus, EGFL7 is necessary for tubulogenesis but 
the mechanism remains unclear. A further study by Durrans et al (2010). showed that the 
deletion of EGFL7 in the embryoid body model, which is a cluster of cells stem cells 
representing the three germ layers, resulted in the formation of abnormal endothelial cell 
aggregations lacking basement membrane and cell junctions [101]. In summary, EGFL7 
is a key protein necessary for vasculogenesis. 	  	  	  
1.2.6 EGFL7 and miR-126 relationship in endothelial cells 
miRNAs are a class of 22 nucleotide long, non-coding RNA molecules that are 
important regulators of protein expression. Importantly, a single RNA molecule can 
regulate a repertoire of proteins globally [102]. These RNA molecules bind to target 
messenger RNA molecules to repress translation or to a lesser degree cause protein 
degradation. In recent studies, of paramount importance is the role of miR-126 in 
angiogenesis and tumor progression.  Interestingly, miR-126 is located in intron 7 of the 
EGFL7 gene and is specifically expressed in the endothelial cell lineage, hematopoietic 
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progenitors and a number of tumors. There have been two papers studying the role of 
miR-126 expression in endothelial cells of zebrafish and mouse [80,103]. Loss of miR-
126 causes compromised vessels with collapsed vessel lumens and impaired endothelial 
organization. At the molecular level, miR-126 represses (Sprouty-related, EVH1 
domain-containing protein) SPRED1 and p85 (subunit of PI3K) which negatively 
regulate VEGF and inhibit angiogenesis. Thus, miR-126 indirectly promotes 
angiogenesis. The vascular effects seen in miR-126-/- mice is reminiscent of loss of 
EGFL7 described earlier by Schmidt et al (2010). The mice were born with 50% 
embryonic lethality and vascular	  defects	  with	  hemorrhaging,	  thickening	  or	  aggregated 
sprout morphology and delayed angiogenesis. This evidence suggests that the vascular 
phenotype observed with EGFL7-/- may be likely due to the loss of miR-126. To resolve 
this, Parker et al (2004), used a knockdown approach to lower both miR-126 and EGFL7 
and compared the phenotypes. In both cases, the vessels had compromised lumens and 
hemorrhage was apparent. Certain distinct differences however were noted: In EGFL7 
knockdown angioblasts fail to separate to form lumens but in miR-126 knockdowns 
lumens form but collapse later in development. The role of EGFL7 in tubulogenesis 
however does not reflect the function of miR-126. Two morpholinos were previously 
used to knockdown EGFL7 in zebrafish preventing EGFL7 mRNA translation or caused 
termination of translation [104]. Levels of miR-126 were not affected. The phenotypes 
associated with the loss of EGFL7 were rescued with injection of EGFL7 mRNA. This 
suggests the EGFL7 is the major player of tubulogenesis. However, potential interference 
with pre-mRNA formation and miR-126 maturation can occur using a morpholino. In 
summary, mir-126 is essential for enabling proper angiogenesis during the formation of 
vessel. The transcription of miR-126 seems less likely to be achieved by its own 
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promoter but rather be mediated by the promoter of its host gene-EGFL7 [80]. Although 
it has not yet been observed, it is likely that miR-126 arises from one of EGFL7s pre-
mRNA transcripts. A study has shown that miR-126 expression depends on two regions 
with ETS binding sites located in the 5’end of the EGFL7 gene [105]. However, tissue 
expression of miR-126 and EGFL7 are not strictly linked in many tissue, so they may not 
be co-regulated [77]. Whether miR-126	  expression	  in	  addition	  to	  expression	  of	  EGFL7	  is	  connected	  has	  yet	  to	  be	  investigated.	   
	  
	  
1.2.7 EGFL7 expression and tumorigenesis 
EGFL7 is not only expressed in endothelial cells but also abundantly expressed in 
a number of cancer cell lines. It’s expression is elevated in human tumors such as 
glioblastoma [109], hepatocellular carcinomas (HCC’s)[108], colon cancers[107], and 
non-small cell lung cancer[110]. In gliomas, EGFL7 expression has been correlated with 
increased microvascular density and cell proliferation [107]. Particularly in gliomas, 
EGFL7 expression is localized to tumor cells but also the vasculature surrounding it. This 
suggests that EGFL7 may indeed act in an autocrine, paracrine manner or through cross 
talk between endothelial cells. The exact mechanisms of EGFL7 cross talk between 
endothelial cells and tumor cells however remain to be investigated. In the HCC model 
however, EGFL7 knockdown resulted in decreased metastasis with reduced vascular 
density in comparison to control tumors, which were injected with normal cells [108]. 
This further supports the idea that tumor angiogenesis is regulated by EGFL7. Expression 
of EGFl7 in this cell line in in vitro studies further showed that down regulation of 
EGFL7 affected migration without changing proliferation. In another study, EGFL7 has 
30	  
	   	   	   	   	   	   	   	   	   	  
been positively correlated with tumor stage in colorectal cancer [109]. Specifically, 
EGFL7 expression was found to be highest in stage III and stage IV with increased 
lymph node metastasis. In glioma’s, high expression of EGFL7 has also been correlated 
with increased Ki-67, a marker for prognostic indicator of gliomas [109]. All together 
these data suggests that EGFL7 expression in tumors is correlated with poor prognosis 
and invasiveness of	  many	  cancer	  types,	  adding	  value	  to	  its	  potential	  for	  a	  therapeutic	  target	  and	  prognostic	  marker	  in	  patients.	  	  	  	  	  	  	  	  	  	  	  	  	  	   The mechanisms by which tumor EGFL7 exerts its effect are not clearly undertood. 
In the case of HCC, since EGFL7 is localized to the tumor it is hypothesized that it may 
act in a paracrine fashion. One mechanism this may occur is through activation of Notch 
signaling. Inhibiting notch signaling in tumors by using a Notch 1 decoy, soluble form of 
notch receptor results in a decreased angiogenesis[111]. Reminiscent to this phenotype is 
inhibiting EGFL7, also resulting in reduced tumor angiogenesis. However, the benefits of 
inhibition of the Notch pathway in comparison to EGFL7 inhibition in tumor models over 
long-term needs to be investigated because Notch inhibition has been associated with 
adverse side affects [112,113]. These side affects include disorders of multiple organs 
and developments of vascular tumors.  Given that EGFL7 over-expression in mice 
endothelial cells results in abnormal vessel patterning and remodeling, it is possible that 
abundant EGFL7 secretion by tumors in the micro-environment contributes to the 
irregular, leaky and tortuous vessels characterized in most tumors.  	  	  	  	  	  	  	  	  	  In another study by Fung et al [125], we have showed that EGFl7 however acts to 
inhibit tumor angiogenesis (Fig1-10). In this particular study, EGFL7 constructs were 
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over-expressed in an aggressive fibrosarcoma cell line, HT1080. Expression of EGFL7 
resulted in inhibition of tumor growth in vivo and had a negative effect on tumor 
progression from a primary site to a secondary site. After performing in vitro and in vivo 
angiogenesis assays it was observed that EGFL7 decreases angiogenesis. Interestingly, 
over-expression of EGFL7 increased permeability. A closer analysis of sprout 
morphology revealed vessels consisting of a thickened multi-layered endothelium. These 
data suggest that EGFL7 can also act as an inhibitor of angiogenesis	   in	   tumors,	  contrary	  to	  its	  requirement	  in	  endothelial	  cells	  during	  sprouting	  angiogenesis.	  The	  mechanism	   for	   this	   alternative	   function	   which	   is	   cell-­‐context	   dependent	   seems	  unclear.	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Fig 1-10. EGFL7 Reduces Angiogenesis in vivo 
When HT1080 fibrosarcoma cells were transfected with an EGFL7 construct, HT1080 
EGFL7 GFP, reduced angiogenesis was observed in the chick chorioallantoic 
membrane compared to control HT1080 cells and baseline untransfected HT1080 
cells. This is indicative that EGFL7 acts to inhibits HT1080 tumor angiogenesis. Data 
was processed using Graphpad Prism software.  Statistical significance was 
determined with the  Tukey’s  test,  ***, p<0.001. Columns , mean; bars, SEM. The 
data are representative of three consecutive experiments . Study by Fung et al [125] 
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A recent study shows that EGFL7 is also involved in tumor growth through preventing 
the evasion of host immune cells to the site of the primary tumor [114]. EGFL7 over-
expression in lung and breast cancer in immunocompetent mice reduced the expression of 
leukocyte adhesion molecules vascular adhesion molecule-1 (VCAM-1) and intracellular 
adhesion molecule-1 (ICAM-1). This ultimately represses immune cell infiltration to the 
site of the primary tumor, thus escaping immune evasion. 
	  
1.2.8 EGFL7 as a therapeutic target  
Given that EGFL7 is implicated in tumor angiogenesis, invasiveness and 
metastatic progression, EGFL7 is an ideal therapeutic target. Human clinical trials have 
been underway combining avastin, an anti-VEGF treatment, with anti-EGFL7 antibodies. 
This study has shown that human cancer xenografts treated with anti-VEGF and anti-
EGFL7 results in an additional inhibition of tumor growth than anti-VEGF alone . This is 
expected, considering that both VEGF and EGFL7 are important players in tumor 
angiogenesis. It is possible that the use of anti-EGFL7 will contribute to the 
normalization of vasculature, given its role in vessel remodeling, and thus can extend the 
therapeutic window for drug delivery of avastin or other drugs. Although this study is 
promising, the overall long-term outcome and side effects of anti-EGFL7 treatment needs 
to be further investigated.   
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1.2.9 The role of miR-126 in tumorigenesis 
 
In the recent past, miRNAs have been identified through transcriptional profiling 
and micro-array analysis as key regulators of various pathways during tumorigenesis. 
These microarrays reveal significant difference in expression when comparing tumor 
burdened tissue with non-cancerous tissue [115]. Recently, miR-126 has been shown to 
have a tumor suppressive role in a variety of cancers. In breast cancer, miR-126 is lost 
and patients with primary tumors characterized by low miR-126 levels displayed poor 
overall-metastasis free survival in comparison to patients with high levels of miR-126 
[116]. This data suggests that miR-126 is associated with metastasis free survival, a 
clinical correlation that can be used to assess treatment approaches. Down-regulation of 
miR-126 has further been observed in cancers of stomach, lung, bladder, prostate, colon 
[118-121]. It has been reported by Liu et al (2009) that miR-126 has a role in 
downregulating VEFG-A, after inoculation of lung carcinoma cell lines with a lentivirus 
containing miR-126 [122]. The resulting observations were inhibition of tumors due to 
cell cycle arrest.  Furthermore, treatment of breast cancer lines with a Src kinase inhibitor 
protein phosphatase 2 (PP2)  caused increased levels of miR-126 with subsequently 
decreased migration [123]. In another study, Guo et al (2008). showed loss of miR-126 
resulted in impaired signaling in the phosphatidylinositol (PI3K) pathway, which enabled 
enhanced migration of colon cancer cells [106]. In particular, gastric cancers with high 
levels of miR-126 inhibited tumor metastasis both in vitro and in vivo.  	  
A recent study by Png et al (2011), showed that miR-126 expression in metastatic 
breast cancer cell line mediates endothelial cell recruitment [124]. Specifically, miR-126 
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expression suppresses metastatic colonization, angiogenesis and endothelial recruitment 
by targeting insulin-like growth factor binding protein 2 (IGFBP2), phosphatidylinositiol 
transfer protein cytoplasmic 1(PITPNC1) and c-Mer tyrosine receptor kinase  (MERTK). 
These are genes associated with metastasis and are often used as a biomarker for 
metastasis.  	  	  
The transcriptional regulation of miR-126, however with respect to EGFL7 is not 
completely understood. Tumors that normally have elevated levels of EGFL7 expression 
have low levels of miR-126. Given that miR-126 is part of EGFL7, it is likely in this case 
a separate mechanism drives miR-126 expression and EGFL7 expression in the 5’end 
promoter region of EGFL7. How mir-126 is regulated independently of EGFL7 is yet to 
be understood.   	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1.2.10	  Research	  Motivation	  
The expression of EGFL7 and its role in tumor angiogenesis still remains unclear. 
It has been shown that EGFL7 expression is upregulated in the tumor microenvironment 
and associated with invasivness, however, our group has shown that the expression of 
EGFL7 by aggressive fibrosarcoma tumor cells is inhibitory on angiogenesis both in vitro 
and in vivo. In contrast to its inhibitory effect on angiogenesis, endothelial expression of 
EGFL7 is rather necessary and promotes the proper orientation and spatial organization 
of a developing sprout during angiogenesis. This suggests that the opposing function of 
EGFL7 on tumor angiogenesis is cell-context dependent. Given that EGFL7 exhibits 
opposing functions during angiogenesis based on whether it is expressed by endothelial 
cells or tumor cells, I investigated how EGFL7 is differentially regulated in tumor cells in 
comparison to endothelial cells during tumor angiogenesis. 	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1.2.11 Hypothesis 
The production of alternative transcripts from the EGFL7 locus in tumors mediates an 
inhibitory impact on tumor angiogenesis 
 
1.2.12 Objectives 
The main objective of this work is: Determine the basis of differential effects of EGFL7 
on tumor angiogenesis  
 
The specific objectives of this work are: 
1. Characterize and map the transcripts that are produced in human endothelial cells 
and HT1080 tumor cells  
2. Establish a knockdown model of individual transcripts produced from the    
EGFL7 locus in HT1080 tumor cells 
3. Assess the function of EGFL7 transcripts produced in tumor cells on tumor     
angiogenesis 	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2.1 Introduction	  
De novo angiogenesis is an essential process necessary for tumor growth, its 
progression and a mechanism for cancer metastasis. The growth of a large tumor is often 
accompanied by a sustained release of angiogenic factors in the tumor microenvironment, 
switching the angiogenic balance favoring blood vessel formation [1,2]. This is often 
initiated by a hypoxic tumor microenvironment and subsequent release of growth factors 
that bind to quiescent endothelial cell receptors through paracrine mechanisms [3]. Upon 
activation, endothelial cells release MMP’s that degrade the basement membrane and 
surrounding extracellular membrane. Other factors such as VEGF contribute to 
increasing the permeability of vessels as endothelial cell loosen their junctions [4]. The 
release of ECM proteins by endothelial cells and tumor cells, in addition to plasma 
proteins, creates a permissive microenvironment for sprouting angiogenesis to occur. 
Endothelial cells acquire a tip-stalk phenotype, where the tip cells are filopodia rich cells 
directing the sprout towards the tumor and stalk cells proliferate to elongate the sprout 
[5]. There are many signaling pathways that are activated and coordinated in 
physiological angiogenesis but in the context of tumors many pathways are deregulated. 
More specifically, tumor cells increase VEGF and FGF secretion, contributing to 
sustained angiogenesis but also tortuous, leaky and irregular vasculature [6]. In the tumor 
microenvironment the source of ECM factors are not only restricted to tumor cells but 
endothelial cells and other cell types. Some of these ECM factors act in paracrine and 
autocrine mechanisms.  	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EGFL7, also known as epidermal growth factor like-7 protein, is a secreted ECM 
protein with an apparent mass of 30kda. EGFL7 is unique in that endothelial cells express 
EGFL7 and is normally not expressed in the adult vasculature [7]. However, EGFL7 
becomes upregulated during angiogenesis, such as in pregnancy [8], wound healing and 
tumor growth [7]. In zebrafish, loss of EGFL7 has resulted in impaired tube formation 
with hemorrhaging [7]. Similarly, down regulation of EGFL7 in mice caused abnormal 
vasculature with 50% deaths in utero [9].  Furthermore, it was observed that EGFL7 
functions by coordinating the proper spatial organization and adhesion of endothelial 
cells during sprouting [8,10]. It is therefore plausible to conclude that EGFL7 expression 
by endothelial cell is a requirement for proper angiogenesis. 	  
In tumors where leaky, irregular vasculature is apparent, EGFL7 is upregulated by 
tumor cells. Elevated EGFL7 levels have been observed in glioma [11], hepatocellular 
carcinoma [12] and non-small cell lung cancer [13,14]. Increased expression of EGFL7 
has been correlated with poor prognosis, increased metastasis and invasiveness of cancer 
cells. However, the function of EGFL7 during tumor angiogenesis remains elusive. In an 
in depth analysis by our group we have shown that EGFL7 expression in the human 
fibrosarcoma tumor inhibits angiogenesis both in vitro and in vivo using the chick 
chorioallantoic membrane. Importantly, we observed reduced metastasis and increased 
vascular permeability. After analyzing the sprout morphology through electron 
microscopy we were able to conclude that EGFL7 over-expression results in thickened, 
aggregated sprout morphology (unpublished data). Thus, we concluded that EGFL7 has 
an inhibitory effect on angiogenesis.  EGFL7	   is	   necessary	   for angiogenesis or proper 
sprout formation when expressed by endothelial cells, however when expressed by tumor 
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cells it is inhibiting angiogenesis, which interestingly is contrary to the need of 
vasculature for tumor growth. It seems that the location of EGFL7 expression is critical 
to its function. In this context, expression of EGFL7 by tumor cells is inhibiting 
angiogenesis, however when expressed by endothelial cells it promotes angiogenesis. 
Given the fact that EGFL7 in tumor cells and endothelial cells has opposing effects on 
angiogenesis, the question is how EGFL7 is being differentially regulated in these cell 
types and its impact on angiogenesis. We hypothesized the opposing phenotypes are due 
to the differential regulation of EGFL7. Specifically, we investigated whether there are 
alternative EGFL7 transcripts in fibrosarcoma tumor cells as compared to endothelial 
cells and its subsequent impact on tumor angiogenesis.	  	  	  
The EGFL7 locus comprises 10 exons spanning just over 10kb. Exon 3 through to 
Exon 10 is the open reading frame of the EGFL7 gene, where Exon 3 is the translation 
initiation site ATG [15,16]. The 5’end region upstream of exon 3 has two untranslated 
exons and two transcriptional start sites. It is not known what transcripts are produced 
from these transcriptional start sites or how these transcripts impact angiogenesis. 
Previous studies have shown that the 5’end regulatory region contains GATA and ETS 
binding sites that modulate endothelial EGFL7 expression. Importantly, miR-126, a 
microRNA located in intron 7 of EGFL7 is likely also regulated from the 5’end 
regulatory site [16]. Investigating what alternative transcripts are produced from the 
EGFl7 locus in tumor cells as compared to endothelial cells may also reveal whether 
miR-126 is processed from any of its transcripts.  
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2.2	  Materials	  and	  Methods	  	  
Cell Culture 
The human HT1080 fibrosarcoma cell line is an aggressive tumor cell line that 
was extracted through serial passaging through the avian embryo. These cells were 
maintained in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% FBS 
with a rate of doubling every two days. Cell passages used for experiments were between 
passages 10-20. Human umbilical vein endothelial cells (HUVECs) were collected as 
previously decribed [] and grown in endothelial growth medium (EGM) up to 4 passages 
and supplemented with Brain Bovine Extract (BBE). All cells were cultured at 37 °C in 
5% CO2 /95% O2. HT1080 EGFL7 over-expressing cells were generated as previously 
described []. 
 
siRNA Transfections 
Cells were seeded into  6 well plates at a density of 1.5 X 105 cells/well and 
supplemented with DMEM containing10% FBS. After one day of adhesion cells were 
transfected using silentfect (biorad) with 20nM of siRNA Ex5 
5’CCAUCUAUAGGACCGCCUAUU’3, siRNA Non-cod (targets the non-coding 
transcript) 5’AUCCGGCGCCGUAGGGUGUGUUU’3  or scramble siRNA 
5’GAAGUAACACCCGCACCUAUU’3. HT1080 cells were treated for 48hrs or 72hrs 
after transfection with siRNA Ex5 and siRNA non-coding respectively.  	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Western Blot 
Cells were lysed with lysis buffer (150mM NaCl, 0.01% NP-40, pH 7.4, 50mM Tris). 
Cell pellets were then re-suspended in urea buffer (10mM NaCl, 1mM DTT, 20mM Tris-
HCL, 4 M urea, pH 6.0) with protease cocktail inhibitor. Protein concentrations were 
then measured using the Bradford assay (Bio-Rad). Primary antibodies were anti-human 
EGFL7 antibody (1:500, R&D Systems) and tubulin (1:20 000). Secondary horseradish 
peroxidase-conjugated mouse anti-goat IgG (1:10 000; Sigma) or anti-mouse (1: 20 000; 
GE Healthcare) were also used. To detect the presence of protein Amersham ECL plus 
western blotting detection system was used (GE Health Care). Positive control for 
experiments was HT1080 over-expressing EGFL7 cell line and negative control was 
scramble/negative siRNA.  
 
RT-PCR and qPCR 
After transfection, RNA was collected using trizol-choloroform extraction according to 
manufacturers instructions (Invitrogen). RNA was DNase treated and subsequently was 
primed with oligo-dT or random hexamers for cDNA synthesis (Invitrogen). RT-PCR 
cDNA was used as a template for either real-time qPCR or standard PCR (BioRad). 
Primers used to pickup transcripts included  
Fwd TSS1: 5’GCTGCAAGGGAGGCTCCTGT’3                              
Fwd TSS2: 5’GCGCGTGCGCGCCCCGGATCG’3, 
Rev Ex2-4:5’AGCCCGCTGGTCCTCTTCCA’3,  
Fwd TSS2Ex4: 5’GGATCCGGCGCCGTAGGGTG’3 
Rev Ex3: 5’CCGCCCACTGCCAACACCAGA 
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Real-time PCR template levels were detected using a SYBR green reagent and measured 
relative to GAPDH levels. Bands were gel-extracted, cloned into a pGEM-T vector 
(provided by Promega) and sequencing at Robarts research facility, Western university. 
 
Quantitative analysis of miR-126 expression  
Total RNA of cells was extracted using trizol-chloroform extraction according to 
manufacturer’s instruction (Invitrogen). Expression of miR-126 was analyzed using 
Taqman microRNA assay. RNA was reverse transcribed using a looped RT primer 
specific for mature miR-126 and standardized to miR-16 expression levels. Real-time 
PCR was then used to detect the levels of miR-126. The assay was performed in triplicate 
and results are of 3 independent experiments.  
 
In Vitro Angiogenesis assay 
In vitro angiogenesis/morphogenesis assay was performed as previously described 
(Becton Dickinson, Mississauga). Briefly, matrigel was diluted with chilled endothelial 
growth medium (EGM; Gibco) in a 1:2 ratio and coated onto a 96 well plate (50uL). 
Matrigel was then left to polymerize for 30-40 minutes at 37°C. HUVECs less then 4 
passages were cultured in EGM with 5% FBS (Lonza) and plated onto the Matrigel at a 
density of 1.5 X 104 cells/well in EGM supplemented with 0.5% FBS. HT0180 
transfected cells were dislodged using trypsin and co-cultured with HUVECs at a density 
of 7500 cells/well. Cells were incubated at 37° C in 5% CO2/95% O2. Wells were imaged 
at 2hr, 6hr and 11hr time points using an inverted phase contrast microscope at 10X 
magnification. Angiogenesis or endothelial tube formation was assessed by counting 
number of branch points in at least 10 random fields of view using Image J software. 
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HT1080 and HT1080 EGFL7 cells were used as positive and negative control, 
respectively. Each treatment was performed in quadruplets and results represent at least  
three independent experiments. 
 
 
Statistical Analysis 
Data was analyzed using Graphpad Prism software (Graphpad software Inc. San Diego). 
One way Anova with post-hoc Tukey test or  student T-test using post-hoc Mann-
Whitney test was used to determine significance. All columns and corresponding error 
bars represent the mean or standard error of the mean (SEM), respectively. 
	  
	  
2.3	  Results	  	  
	  
Endothelial cells express both a long and short family of transcripts originating 
from TSS1 and TSS2 respectively 
 
To determine what transcripts are produced from the EGFL7 locus, we used HUVECs, 
because EGFL7 expression is abundant in these cells and required for angiogenesis. 
Primers were designed along different regions of the EGFL7 gene according to ensemble 
based EST database. Here we show that endothelial cells express two families of 
transcripts (Fig 2-1), either a long (Fig 2-1 A-D) or short family of transcripts (Fig 2-
1E,F), which originate from transcription start site 1 (TSS1) or TSS2, respectively. TSS1 
based transcripts comprise a coding and non-coding transcript. Based on sequence 
analysis of gel-extracted bands the non-coding splice variant lacks exons 3 which 
contains the ATG element needed for translation. Similarly, the TSS2 family of 
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transcripts also comprises a coding and non-coding transcript, which lacks exon 3 and 
was uniquely identified using specific primers.  	  
Tumor cells express only TSS2 short family of transcripts and not TSS1 transcripts 
 
Knowing that EGFL7 is also secreted by a variety of cancer cells [11,12,13,14], I then 
investigated what EGFL7 transcripts are produced in a metastatic tumor cell line, human  
fibrosarcoma (HT1080), in comparison to endothelial cells. Using a fwd TSS2 primer 
with different reverse primers, showed that HT1080 cells express TSS2 originating short 
family of transcripts (Fig 2-2A). Interestingly, HT1080 cells do not express any long 
family of transcripts originating from TSS1 in comparison to endothelial cells (Fig 2-2B). 
After sequencing analysis and unique amplification, the short family of transcripts 
comprise a coding and non-coding sequence, which lacks exon 3 necessary from EGFL7 
translation (Fig 2-2 C-E). The levels of coding and non-coding transcripts produced in 
HT1080 cells were similar, however, the overall level of EGFL7 protein produced 
endogenously in HT1080 cells was 2-fold less then HT1080 EGFL7 over-expressing 
cells (Fig 2-3).  
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Fig	  2-­1.	  Endothelial cells express two families of transcripts either from TSS1 or 
TSS2, both comprising a coding and non-coding sequence. 
A) RT-PCR of transcripts in human endothelial cells originating from TSS1 with a common 
TSS1 forward primers (FwdTSS1) and reverse primers at exons 4 (Rev4) and 8 (Rev8). The 
upper band indicates a coding transcript where exon 3 is intact, whereas the lower band is 
representative of a non-coding transcript lacking exon3. Transcripts were gel extracted and 
sequence verified using a pGEM-T vector. B) Schematic of transcripts produced from TSS1. C) 
RT-PCR that uniquely identifies the non-coding transcript in endothelial cells as part of TSS1 
family of transcripts. The primers used are a Fwd TSS1 primers and a reverse primer that 
overlaps exon 2 and exon 4 (RevEx2-4) D) Schematic figure of the non-coding transcript in 
endothelial cells with a unique reverse primer (RevEx2-4). E) RT-PCR of transcripts originating 
from TSS2 using a primer set that is either specific to the coding transcript (TSS2Rev3) or the 
non-coding transcript (TSS2Ex4Rev5). Unique identification of transcripts are due to the 
presence (coding) or absence of exon 3 (non-coding). F) Schematic of TSS2 transcripts produced 
from endothelial cells.  All transcripts were gel extracted and sequence verified using a pGEM-T 
vector. Colored boxes indicate ORF exons and uncolored boxes are representative of the 5’end 
untranslated exons.  
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Fig 2-2. HT1080 tumor cells only express short family of transcripts originating 
from TSS2. 
 
A)RT-PCR of TSS2 family of transcripts produced in HT1080 tumor cells using primers specific 
for coding (TSS2Rev3) or both coding and non-coding (TSS2Rev4). The lower band in 
TSS2Rev4 is indicative of the non-coding transcript based on sequencing analysis whereas the 
coding is of a higher molecular weight. B)RT-PCR using a fwd TSS1 primer didn’t show the 
presence of any transcripts in HT1080 tumor cells. C)Schematic of the TSS2 family of transcript 
expressed in tumor cells with fwd and reverse primers. D) RT-PCR of the non-coding transcript 
expressed in HT1080 tumor cells. E) Schematic of the non-coding transcript with a unique fwd 
primer (FwdTSS2Ex4) and a reverse primer (Rev5).  All transcripts were gel extracted and 
sequence verified using a pGEM-T vector. Colored boxes indicate ORF exons. 
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Fig 2-3. Endogenous levels of transcripts produced in HT1080 cells. 
A)	  Quantification of endogenous levels of transcripts produced in HT1080 tumor cells using 
qPCR. The relative expression of transcripts was detected using primers specific for each 
transcript and normalized to GAPDH. Results are in arbitrary units. No significant difference 
between coding transcript and non-coding transcript levels were detected (p=0.46). Columns, 
mean of three replicates, bars, SEM. Expression normalized to GAPDH. B) Western blot data of 
endogenous EGFL7 levels in HT1080 cells relative to HT1080 EGFL7 over-expressing cell line. 
Tubulin was used as a loading control.	  	  
	  
	  
 
 
 
 
 
 
 
 
 
	  	  A	   	  	  B	  
62	  
	   	   	   	   	   	   	   	   	   	  
Transcripts knockdown validation data 
Once the different type of transcripts produced by tumor cells were known, I designed 
siRNA Ex 5 that targets exon 5 of both coding and non-coding transcripts or siRNA non-
coding that uniquely targets the non-coding transcript. Knockdown is achieved after 
transfection of cells using a lipid-reagent. Ultimately, the transcript is repressed or 
degraded.   siRNA Ex 5 reduced both coding  and non-coding transcript levels relative to 
scramble siRNA (p<0.05)(Fig.2-4,A). Western blot analysis also shows that siRNA Ex 5 
affects EGFL7 production due to targeting EGFL7 coding transcript, however, the non-
coding siRNA doesn’t affect EGFl7 protein levels as expected (Fig2-4,B).  This was 
further validated through qRT, which shows that the coding transcript isn’t affected by 
siRNA non-cod but significantly reduced by siRNA Ex 5 (p<0.05)(Fig 2-4C). The non-
cod siRNA, however, significantly reduced non-coding transcript levels relative to 
negative siRNA (p<0.001) (Fig 2-4D).  	  
miR-126 expression is not affected after knockdown of transcripts  
Since miR-126 regulation has previously been affected by EGFL7 knockdown [125], as 
its regulation remains unknown despite its important role in mediating angiogenesis, I 
investigated whether transcripts produced from HT1080 tumor cells can affect miR-126 
regulation. Briefly, mature miR-126 was reverse transcribed using stem looped a RT-
primer and levels were standardized to miR-16 levels, which is a constitutively expressed 
gene. The expression of miR-126 is not affected knockdown of both coding and non-
coding transcripts.(Fig. 2-5). 
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Fig	  2-­4.	  Knockdown	  validation	  of	  both	  coding	  and	  non-­coding	  transcripts	  in	  HT080	  
tumor	  cells.	  	  
A)Real time quantification showing siRNA Ex 5 significantly lowers both non-coding and coding 
transcript levels compared to a negative control siRNA negative. Expression is normalized to 
GAPDH. * p<0.05, **p<0.01 . Columns, mean of 3 replicates; bars, SEM. B) Western blot &  C) 
real time analysis showing siRNA Ex.5 knockdown of EGFL7 relative to siRNA Non-cod, 
targeting the non-coding transcript or control siRNA. Non-coding siRNA does not affect EGFL7 
levels or alternatively protein coding transcript levels. **p<0.01. Columns, mean of 3 replicates; 
bars, SEM. Expression normalized to GAPDH. D) siRNA non-cod significantly knocked down 
non-coding transcipt relative to scramble.***p<0.001. Columns, mean of 3 replicates; bars, SEM. 
	  	  A	   	  	  B	  
	  	  C	   	  	  D	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Fig 2-5. miR-126 levels are not affected by knockdown of both transcripts in 
HT1080 tumor cells. 
 
Levels of miR-126 was quantified by qPCR after knockdown of both transcripts with siRNA Ex 5 
amd non-coding transcript using siRNA Non-cod . The relative expression of miR-126 was 
detected using a looped-RT primer which specifically detects mature miR-126 levels. Data was 
normalized to miR-16 standard. No significant difference between negative siRNA and siRNA 
Ex 5 was observed (p=0.100). Columns, mean of 3 replicates; bars, SEM. Data is representative 
of 3 independent experiment.  
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EGFL7 transcripts play a role in inhibiting tumor angiogenesis 
Knowing what alternative transcripts are produced in tumor cells the next 
question was to understand the functional role of these transcripts during tumor 
angiogenesis. An in vitro angiogenesis assay was done co-culturing human endothelial 
cells (HUVECs) with HT1080 cells containing transcript knockdowns. Lowering levels 
of both transcripts in HT1080 cells resulted in significantly enhanced angiogenesis 
relative to HT1080 cells alone cultured with endothelial cells (p<0.05) (Fig. 2-6).  As a 
negative control we further confirm that EGFL7 over-expression reduces angiogenesis 
relative to control HT1080 (p<0.05), based on previous preliminary data. In summary, 
this data suggests a novel role for both coding and non-coding short family of transcripts 
produced from TSS2 of the EGFL7 locus within HT1080 tumor, which act to inhibit 
angiogenesis in the tumor microenvironment.  
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Fig. 2-6. HT1080 TSS2 family transcripts inhibit angiogenesis in vitro 
HUVECs (1.5 X 104 cells/well) were seeded into a 96-well plate pre-coated with matrigel and co-
cultured with treated or control HT1080 cells (1.5X103 cells/well). Controls included HT1080 
cells, cells over-expressing EGFL7 and negative siRNA treated cells. Treatment groups were 
knockdown of either both transcripts or specifically the non-coding transcript using siRNA Ex 5 
or siRNA non-coding, respectively. Knockdown of both transcripts or non-coding transcripts 
significantly enhances angiogenesis, whereas over-expression reduced angiogenesis relative to 
control HT1080 cells. Below are representative phase-contrast images of endothelial tube 
formation on matrigel. *p<0.05 relative to HT1080 control. Columns, mean; bars, SEM. Scale 
Bar, (250μm). The data is representative of at least 2 independent experiments.  
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2.4 Discussion 
In this study I show that EGFL7 is differentially regulated in tumor cells as 
compared to endothelial cells by producing only TSS2 family of transcripts. Importantly, 
this family of transcripts in tumor cells inhibits tumor angiogenesis. In endothelial cells 
however, both TSS1 and TSS2 families of transcripts are produced in which EGFL7 in 
this context is a requirement for angiogenesis. Interestingly, both families of transcripts 
produced 2 alternative variants of EGFL7-a coding transcript in which exon 3 is intact 
and a non-coding transcript lacking exon 3. The differential regulation of transcripts may 
be a potential mechanism for EGFL7s opposing function on angiogenesis.  
 
EGFL7 produces 4 alternative transcripts that are different by family based on the 
origin of transcription at the 5’ end or intra-family variability is observed by the splicing 
or inclusion of exon 3.  In the context of intra family variability, tumor cells produce 
TSS2 family of transcripts, one transcript that is a protein coding sequence and the other 
a non-coding processed transcript. Factors determining what exons are spliced or 
included during splicing, can result in a repertoire of proteins from a single gene with 
multiple functions[18,19]. Moreover, tissue dependent splicing patterns are regulated by 
many trans-acting factors or cis-acting RNA sequence motifs [17]. In the context of 
splicing regulations, EGFL7 exon3 exclusion results in a non-coding sequence with no 
protein being produced, since it is the ORF of EGFL7. The generation of a non-coding 
RNA, which are often greater than 200 nucleotides, are crucial in global gene regulation 
and protein function [20,21,22,23]. For example, HOTAIR long-noncoding RNA 
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(lncRNA) expression is increased in breast tumors and its over-expression in non-
invasive cell lines enhanced metastasis and invasiveness [24,25]. This is due to its ability 
to cause genome-wide changes in methylation patterns in many tumor suppressor genes. 
It is therefore suggested that HOTAIR can serve as a diagnostic bio-marker for cancer 
patients. However, this is the first study to show a role of lncRNA expressed in tumor 
cells that inhibits angiogenesis. The mechanism of anti-angiogenic activity of TSS2-non-
coding transcript in tumor cells thus, may be meditated by causing chromatin 
modifications of pro-angiogenic genes, repressing transcriptional activity. This can be 
further studied using chromatin immunoprecipitation studies. 
 
 
EGFL7 transcripts produced in HT1080 tumor cells only are TSS2 family of 
transcripts and lack TSS1 transcripts, whereas endothelial cells express both families. 
These families of transcripts are different because there are transcribed from different 
transcriptional start sites, thus they have different 5’UTRs, where TSS1 is a longer 
transcript than TSS2. However, all transcripts contain the same ORF. Given this finding, 
it is possible that the opposing role of EGFL7 in these cell types stems from differential 
expression of these transcripts due a novel method of 5’UTR regulation. For instance, it 
is possible that TSS2 transcripts have naturally an inhibitory role on angiogenesis as was 
the case in tumors, but in endothelial cells this inhibitory function is repressed. The 
structure of the 5’ UTR in endothelial cells may be different, docking endothelial specific 
inhibitory molecules that repress translation[26].  For instance, the cytochrome P450 1B1 
mRNA involved in metabolism is not abundantly expressed in tumor tissue as compared 
to normal hepatic tissue [27]. After molecular analysis, it was shown that cytochrome 
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P450 1B1 in tumors is repressed due to the nature of its complex 5’UTR. The 5’UTR was 
a site for miRNA-27b to bind, repressing translation. In addition, the 5’UTR contained a 
uORF and mutations in this site promoted the translation of the mRNA due to lack of 
inhibition by 5’UTR proteins.  In the context of endothelial cells, TSS1 may house 
upstream open reading frames (uORFs) in the 5’UTR that may produce a protein with an 
angiogenic promoting function. For instance, the transforming growth factor beta-3 gene 
(TGF-B3), which plays an important role in tumorigenesis and other diverse processes, 
produced two transcripts, 2.6kb and 3.5kb in length [25]. The 3.6 kb transcript has a 
longer 5’UTR with 11 uORFs, whereas the 2.6 kb has 2 uORFs. The longer transcript is 
translationally inhibited in breast cancer cell lines and other cancerous tissue but the 
shorter one is translationally active in breast cancer cell lines. Importantly, Signori et al 
(2010) showed that decreased expression of breast cancer 1 (BRCA1) associated with 
breast cancer is as a result of a point mutation decreasing translation efficiency [25]. It is 
possible, that TSS2 family of transcripts harbor 5’UTR mutations in HT1080 tumor cells 
making them more efficient for translation and subsequent inhibition of angiogenesis, 
where they should normally be repressed. Understanding the precise mechanism of this 
differential expression of transcripts and the reason for exclusive expression of TSS2 
transcripts in tumor cells may provide insights on tumor development in the context of 
angiogenesis.  
 
The knockdown of TSS2 based coding transcript, which is translated to EGFL7 
protein, also resulted in enhanced angiogenesis, suggesting an inhibitory role for TSS2 
transcripts in HT1080 cells. This begs the question as to why HT1080 cancer cells, which 
are highly metastatic, express EGFL7 transcripts that inhibits angiogenesis-a process that 
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favors tumor growth. One potential explanation for this is that tumor cells may want to 
generate a hypoxic microenvironment which permits cancer cell to become more 
invasive, enabling migration and potential metastasis to a secondary site [28,29]. In 
contrast, a reduction in vasculture in tumors can also permit a dormancy of tumor cells, 
enabling growth advantage during more ideal conditions [30]. Competing suppression of 
antiangiogenic factors with pro-angiogenic factors in primary and metastatic tumors 
maintains a balance between apoptosis and proliferation. In mice, the expression of anti-
angiogenic inhibitor, angiostatin, resulted in a dormant state of fibrosarcoma tumor cells 
but once the inhibitor was removed, tumors experienced rapid growth [31].  According to 
Fung et al. [32] another possible explanation of reduced angiogenesis due to EGFL7 is 
that too much EGFL7 in the micro-environment produced by endothelial cells and tumor 
cells can deregulate proper assembly of endothelial cells, therefore inhibiting 
angiogenesis. Too much EGFL7 can potentially cause endothelial cells to improperly 
detect sprouting boundaries and cause cells to clump on one another, resulting in a 
compromised vessel. 
 
 Due to previous attempts to knockdown or knockout EGFL7 resulted in changes 
in miR-126 levels [9], it is important to confirm that the results are not due to major 
alteration in miR-126 levels. There was no change in expression of miR-126 after 
knockdown of both TSS2 transcripts in tumors as expected, since miR-126 is generated 
from a pre-mRNA and thus alterations in mature mRNA shouldn’t affect levels. This 
said, it might be possible that EGFL7 transcripts are associated with miR-126 processing 
at the pre-mRNA level.  
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2.5 Conclusion  
 In summary, this data identifies novel transcripts produced from the EGFl7 locus 
that are differentially expressed in tumor cells as compared to endothelial cells. It is 
possible that this differential expression stems from differences in regulation at the 
5’UTR of TSS1 and TSS2 transcripts. Importantly, we identify TSS2 coding and non-
coding transcripts  as inhibitors of  angiogenesis in tumor cells. Further insight as to the 
mechanism of this differential regulation may shed light on understanding EGFL7 
function and regulation during angiogenesis.   
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Chapter 3: Conclusions, Strengths and Limitations 
3.1 Summary  
Tumor angiogenesis is a necessary process for tumor growth and a mechanism for 
cancer cells to metastasize. There are many signaling cascades in the angiogenic 
environment. Tumor cells secrete factors that act in autocrine fashion or paracrine 
mechanisms, interacting with endothelial cells of the vasculature. Importantly, in tumors 
however, the tight regulation of proper angiogenesis seems to be lost due to abundant 
expression of factors such as VEGF or inhibitory molecules. This accounts for why the 
tumor vasculature appear irregular and tortuous. Understanding how different signaling 
pathways are regulated may shed light on therapeutic possibilities and a better grasp of 
tumor biology. Regulation of signaling molecules can be mediated at many levels such as 
transcriptionally, translationally or even modifications in the protein structure in the 
ECM.  
 
In this study we have identified a novel method of differential regulation for 
EGFL7 through the production of alternative transcripts that may explain why EGFL7 is 
inhibitory in tumor cells.  Interestingly, the TSS2 family of transcripts produced in tumor 
cells, including the non-coding transcript, has an inhibitory role on tumor angiogenesis. 
Understanding how both non-coding and coding transcripts mediates their effects on 
inhibiting angiogenesis will provide further insight into EGFL7 biology, transcriptional 
regulation and presumably miR-126 processing.  
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Objective 1: Characterize and map the specific transcripts that are produced in 
endothelial and HT1080 tumor cells:  
  
In Chapter 2, I demonstrated that there is differential expression of transcripts in 
HT1080 tumor cells in comparison to endothelial cells. It was determined that in 
endothelial cells, the EGFL7 locus transcribes 2 families of transcripts-TSS1 and TSS2. 
Both families comprise a non-coding and coding transcript, based on the splicing or 
inclusion of exon 3, respectively. I further show that in tumor cells, however, only TSS2 
transcripts are transcribed. The differential regulation of EGFL7 is therefore cell-context 
dependent and could be potential reason as to why EGFL7 is inhibitory in tumor cell, 
whereas it promotes angiogenesis in endothelial cells.  
 
 
Objective 2: Establish a knockdown model for individual transcripts transcribed from the 
EGFL7 locus in HT1080 tumor cells 
 
 I also further show knockdown of TSS2 transcripts in tumor cells. After cloning 
trancripts into a pGEM-T vector  for sequencing, siRNAs were designed to effectively 
knockdown transcripts. I showed the successful knockdown of the non-coding transcript 
and that EGFL7 protein levels are not affected. Moreover, siRNA mutually present exon 
5 in both transcripts resulted in lowered EGFL7 levels. This is as a result of knocking 
down the coding version which translates to EGFL7 protein. 
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Objective 3: Assess the function of EGFL7 transcripts produced in HT1080 cells on 
tumor angiogenesis 
 
 In this in vitro angiogenesis assay, knockdown of both TSS2 transcripts, coding 
and non-coding, results in enhanced tumor angiogenesis. This suggests that endogenous 
TSS2 transcripts produced by HT1080 cells is inhibitory in nature. Based on sprout 
morphology, there was no striking difference observed in transcript knockdowns. This 
study further concludes that the non-coding transcript has an inhibitory role on 
angiogenesis. Exactly how a lncRNA mediates this affect remains to be investigated.  
 
3.2 Strengths 
The study is the first to examine what EGFL7 transcripts are produced and how 
these transcripts affect tumor angiogenesis. The role of EGFL7 protein in tumor 
angiogenesis remains elusive to date but this study has opened the window to understand 
EGFL7 biology further in terms of transcriptional regulation and how this may affect its 
function. Specifically, it would be interesting to understand how TSS2 family of 
transcripts presumes an inhibitory role in tumor cells, yet in endothelial cell where 
EGFL7 induces angiogenesis, TSS2 is still transcribed. One way to explore this is to 
over-express TSS1 transcripts in HT1080 cells and observe how TSS2 transcripts are 
affected or alternatively, whether a pro-angiogenic phenotype is observed during 
angiogenesis. Moreover, this study examines the identification of a lncRNA involved in 
angiogenesis. These families of non-coding RNA have global roles in gene and protein 
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regulation and are becoming increasingly important in tumor biology. Understanding 
how TSS2 lncRNA is meditating an inhibitory function on angiogenesis can enable a 
better understanding of the regulatory network of lncRNA on tumor angiogenesis. The 
role TSS2 lncRNA on inhibition of angiogenesis can be meditated by regulating other 
pro-angiogenic genes through chromatin modification such as deacetylation methylation 
or transcriptional interference. It is also possible that this lncRNA may directly bind to 
proteins necessary for angiogenesis.  
 
3.3 Limitations  
One limitation in this study is the lack of understanding of the role of TSS2 
transcripts on tumor angiogenesis in vivo , using the chick CAM.  The HT1080 tumor 
cells on the chick CAM need to be incubated for approximately 4 days to observe its 
effect on angiogenesis. Using an siRNA for this period of time may be ineffective, as 
transcript levels may rise to normal levels. However, a future in vivo study would be to 
use shRNA to have stable knockdowns of transcripts rather then transient knockdowns. 
Furthermore, in order to better elucidate the role of TSS2 transcripts as inhibitory, it 
would have been interesting to over-express these transcripts in endothelial cells to see 
whether an inhibitory function on angiogenesis is acquired. A good future study would be 
to design constructs harboring TSS2-family transcripts and transfecting these transcripts 
in HUVECs or a cell-type that induces angiogenesis. Additionally, due to siRNA 
optimization or design issues, it wasn’t possible to knockdown the TSS2 coding 
transcript specifically without affecting the non-coding transcript. Putative siRNA’s 
targeting exon 3, unique to the coding transcript, resulted in no knockdown. Therefore, 
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optimal designs of siRNAs targeting exon 3 of the coding transcript would be ideal to 
further prove that TSS2 coding transcript expressed in tumor cells is inhibitory.  
Additionally, this study saw no changes in miR-126 levels because of using 
siRNAs which knocks down mature mRNA not pre-mRNA, where most miRNAs are 
processed from. Examining the effect of TSS2 family transcript knockdowns at the pre-
mRNA level may elucidate whether TSS2 transcripts regulate miR-126 processing.  
A major limitation to this study also includes the use of one cell line. Although we 
observed an anti-angiogenic phenotype in HT1080 fibrosarcoma cell line, it is possible 
that other cell types may result in a pro-angiogenic phenotype. This could be due to the 
cell-specific nature of transcriptional regulation of EGFL7 or specific mechanism of 
alternative splicing of EGFL7.  
 
3.4 Future Considerations 
 To understand the differential basis of EGFL7 expression of transcripts 
biochemically, future studies understanding what transcription factors mediate alternative 
transcription will be important. For instance, over-expression of transcription factors and 
association with production of transcripts will be necessary in the HT1080 fibrosarcoma 
cell line. Importantly, the significance of non-coding EGFL7 transcripts on as an inhibitor 
or angiogenesis needs to be elucidated through future chromatin immunoprecipitation 
studies. The role of TSS1 transcripts in promoting angiogenesis can further be identified 
by its over-expression in HT1080 cell line, since it is not expressed. It would be 
interesting to see whether over-expression of this transcripts results in enhanced 
angiogenesis. Overall, differential transcript expression can vary from cell to cell, so 
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understanding the relevance of transcripts on angiogenesis in different tumor cell lines 
can pave the way for diagnostic and therapeutic approaches. 
 
 
3.5 Concluding Remarks  
 The role of EGFL7 during tumor angiogenesis is yet not completely known. 
EGFL7 can act as an inhibitory protein when expressed by HT1080 cells, yet it promotes 
angiogenesis when expressed by endothelial cells. In our case, the differential regulation 
of EGFL7 mediating opposing effects on angiogenesis is cell-context dependent. 
Specifically, the presence of alternative transcripts present in tumor cells may dictate 
inhibitory function of EGFL7 on tumor angiogenesis. Precisely, understanding how 
EGFL7 transcription in tumor cells meditate an inhibitory effect on angiogenesis during 
tumor development, may yield insight in the transcriptional regulation of EGFL7 and its 
potential use as a diagnostic and therapeutic target.  
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Education: 	  
 
Sep 2010-Present    -University of Western Ontario, London, Ontario  
                                -MSc in Medical Biophysics, Molecular Imaging  
                                  to be earned on August 2012 
                                -Thesis: Differential regulation of EGFL7 and miR-126 during tumor   
                                 angiogenesis (Publishing at end of MSc) 
 
Sep 2005- April 2010   -University of Western Ontario, London, Ontario 
                                  -Bachelor’s of Medical Science (BMSc), Honors Basic Medical Science  
                                      earned June 2010 
                                    -Thesis: Characterizing the effects of statins on the rat fed with a high   
cholesterol  diet 
 
 
 
 
 
May 2010-August 2010   
Summer student, London Regional Cancer Program, London, Ontario 
 
• Use of short hairpin RNA’s to knockdown proteins involved in angiogenesis in 
fibrosarcoma cancer cells  
• Learned experimental methodology, such as, tissue culturing, imaging, cloning, 
angiogenesis  and scratch-wound assays 
• Assisted a MSc student with determining the role of confluency on specific mRNA 
expression profiles in fibrosarcoma cells 
 
 
September 2008-April 2009 
Honors Research Project, Department of Medical Science’s, London, Ontario 
 
• Seminar classes on atherosclerosis and aortic valve stenosis from an integrative and 
cross-disciplinary perspective  
• Induced atherosclerosis through a high cholesterol diet and examined the efficacy of 
statins on cholesterol reduction  
• Conducted imaging, biochemical and histological analysis of the liver, aorta and blood 
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May 2007- August 2007  
Summer Research Project, Robarts Research Institute, University of Western Ontario, 
London, Ontario 
 
• Investigated the role of FRS-2 in the regulation of proliferation versus differentiation in 
neurons 
• Learned a variety of techniques in cell biology and biochemistry such as protein assays 
 
May 2006-August 2006 
Summer Research Project, The Hospital for Sick Children, Toronto, Ontario 
 
• Project involved differentiating teratocarcinoma cancer cells into a neuronal phenotype 
using  
various compounds to test the efficacy of differentiation therapy in cancer 
• Investigated neuroblastoma angiogenesis and growth factors that contribute to 
angiogenesis  
 
Jan 2003- August 2003 
Co-op student at Mount Sinai Hospital Pathology Laboratories, Toronto, Ontario 
 
• Obtained specimens from the operating room and assisted the pathologist assistant with 
making cassettes for specimens  
• Explored the gross anatomy of diseased tissue, how they present and their morphological 
appearance 
• Observed how biopsies of such specimens are examined both in the laboratory and 
histologically for diagnostics  
• Trained on how cancer grading and staging are assigned  
 
 
Oral Presentations   
 
Feb/3/2011 
Medical Biophyiscs Seminar, UWO  
• Baktash, N., Ablack, A., Lewis, J.    “Characterizing the role of Epidermal Growth Factor 
like 7 during tumor angiogenesis”  
 
March/6/2010 
Translational Models of Cancer Course, University of Western Ontario, London, Ontario 
• Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. 
(2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the 
National Academy of Sciences of the United States of America, 100(7), 3983-3988 
 
• Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., et al. (2009). 
Development of a second-generation antiandrogen for treatment of advanced prostate 
cancer. Science (New York, N.Y.), 324(5928), 787-790. 
 
Feb/8/2009 
Cardiovascular Physiology Course, University of Western Ontario, London, Ontario 
• Beardslee, M. A., Lerner, D. L., Tadros, P. N., Laing, J. G., Beyer, E. C., Yamada, K. A., 
et al. (2000). Dephosphorylation and intracellular redistribution of ventricular 
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connexin43 during electrical uncoupling induced by ischemia. Circulation Research, 
87(8), 656-662. 
 
 
Poster Presentations 
 
Feb/2011 
• Baktash, N., Ablack, A., Lewis, J. Elucidating	  the	  function	  of	  EGFL7	  independent	  of	  miR126	  during	  tumor	  angiogenesis.	  “Elucidating	  the	  function	  of	  EGFL7	  independent	  of	  miR-­‐126	  during	  tumor	  angiogenesis.”	  Oncology	  Research	  and	  Education	  Day	  (Submitted	  and	  accepted	  for	  presentation)	  
 
 
April/2011 
• Baktash,	  N.,	  Fung,	  L.,	  Pink	  D.,	  Ablack	  A.,	  Lewis.	  J.	  “EGL7	  is	  potent	  endogenous	  inhibitor	  of	  tumor	  angiogenesis”.	  Annual	  Association	  of	  Cancer	  Research	  Conference,	  
Orlando	  Florida	  (AACR)	  	  
 
 
 
Community Volunteer Experience  
 
 
Sep 2009-Present       
Women’s Community Shelter 
 
• Entertain and organize activities for children living at a shelter 
• Take initiative in being a positive male role model for the children who may have been 
part of male dominated family abuse 
 
Oct 2007-Present       
London Regional District Distress Center Helpline, London, Ontario 
 
• Assist callers facing various forms of stress, ranging from depression, loneliness, suicidal 
ideation and abuse in London or surrounding areas 
• Train new volunteers in handling phone conversations  
• Participate in various information sessions with community services that collaborate with 
the Distress Center 
• Usually a 16hrs/month minimum requirement is necessary 
 
 
 
 
 
Aug 2011-Sep 2011 
TBCRU Paddling for a Cure 
• A participant in a one day event raise funds and awareness for breast cancer through 
dragon boat racing competition  
• Also a chance to meet breast cancer survivor’s  
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May 2009-August 2009 
Sick Children’s Hospital Cancer Ward 
 
• Assisted children and families at the cancer ward during my summer research position to 
facilitate my understanding of the importance of research to the clinical and bedside 
setting 
 
May 2007-2009            
University Hospital Intensive Care Unit & Emergency Department  
 
• Provided a caring and guiding environment between patients and families  
• Took leadership in keeping families updated with patient status and communicating 
information to physicians and nurses 
 
 
Professional Associations 
 
 
April 2011-Present 
CIHR-STP Speaker Committee 
• Member of the selection committee for selecting CaRTT speakers for talks at LRCP 
 
Feb 2011- Present 
Molecular Imaging Member 
• Gained Acceptance into the program in september 
• The molecular imaging program comprises of teaching students about applying science 
principles to molecular imaging techniques  
• Mandatory to take a molecular imaging course, attend presentations and monthly talks 
 
 
Aug 2005-June 2010 
Physicians for Social Responsibility Member 
• Participate in this national committee by writing letters to government authorities 
regarding policies that may effect or benefit health which may include pollution policies 
or environmental bills 
 
Certifications 
 
 
2010  
Applied Suicide Intervention Skills Training (ASIST) 
• Certificate of a two day training courses in suicide intervention 
 
 
2010      
Global Appraisal of Individual Needs (GAIN) Short Screener  
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• Participated in the evaluation of a new clinical short screener at the developed from a 
research article on screening individuals facing addiction 
 
2009 
Distress Centre appreciation Certificate for 358 hours of service by the end of 2009 
 
2009 
 Lab Animal Monitoring, Assessment and Intervention Advanced Rat Training  
 
 
2000-2003  
Alliance Francais School of French Completion Certification 
 
 
Honors and Awards  
 
 
2011 
Ontario Graduate Scholarship (OGS) Recipient 
• OGS is given to student who demonstrate strong academic background and a strong 
potential for research during graduate school  $5,000 per term 
 
2011 
Molecular Imaging Travel Grant 
• Travel grant for students in the molecular imaging program $1000 
 
2010 
Recipient of CIHR Cancer Research Technology Transfer (CaRTT) Scholarship  $25,000 
• CIHR award given to students to broaden their cancer research experience by providing a  
training program in cancer biology and method of scientific communication transfer to 
the private/public sectors 
   
2010 
Recipient of Translational Breast Cancer Research $22,138 
• To encourage trainees to conduct research on breast cancer and encourage participation in  
             seminars, conferences and public presentations 
2010 
Schulich School of Medicine and Dentistry Graduate Scholarship  $7,140 
• Given to students with a strong academic average  
2010 
Outstanding Community Contribution Award  
• Awards given to students who have outstanding leadership roles in the London 
community 
2010 
Dean’s Honor Roll  
• Award for academic excellence 
2009 
Dean’s Honor Roll  
• Award for academic excellence                        
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